atypical ductal hyperplasia , ADH (Abkürzung)

Women who have atypical ductal hyperplasia have an increased risk of breast cancer.

Atypical ductal hyperplasia is associated with 2.4-fold risk.

Atypical ductal hyperplasia is usually discovered by mammography and diagnosed with a biopsy of the breast.

Atypical ductal hyperplasia, a benign proliferative disease of the breast with an increased risk for breast cancer.

Atypical ductal hyperplasia (ADH) is an abnormal production of cells within the duct system of the breast.

For example, women who have a history of atypical ductal hyperplasia would be advised to follow screening recommendations that may differ from those of the general population.

It is important to correctly identify, as it can be confused with atypical ductal hyperplasia, cribriform ductal carcinoma in situ (DCIS), and adenoid cystic carcinoma.

Dr. Lagios says that based on his experience, microscopic core needle biopsies of low-grade D.C.I.S. and benign lesions, called atypical ductal hyperplasia, or A.D.H., may be misread 20 percent of the time.

So if you or a close family member has had breast cancer, or you have had radiation treatment or a breast biopsy showing atypical ductal hyperplasia (ADH), talk to your doctor about how often you need a breast checkup.

And though women found to have such precancerous conditions as lobular carcinoma in situ or atypical ductal hyperplasia are also more likely to develop breast cancer, the increased risk is not sufficient to recommend regular M.R.I. screenings, according to the cancer society.

In two series, proliferative lesions associated with an increased risk of breast cancer (lobular carcinoma in situ, atypical lobular hyperplasia, atypical ductal hyperplasia, DCIS) were noted in 37% to 46% of women with mutations undergoing either unilateral or bilateral RRM.